Search results for " ALPHA"

showing 10 items of 1610 documents

Acute and Chronic Captopril, but Not Prazosin or Nifedipine, Normalize Alterations in Adrenergic Intracellular Ca2+ Handling Observed in the Mesenter…

2004

The effect of hypertension and acute (36-h) or chronic (from age 6 to 16 weeks) antihypertensive treatment with prazosin (2 mg kg(-1) per day), nifedipine (50 mg kg(-1) per day), or captopril (50 mg kg(-1) per day) on Ca2+ mobilization due to alpha1-adrenoceptor activation was analyzed in functional studies using arterial rings [four conductance/distributing vessels: aorta, main mesenteric, iliac, and tail arteries and two resistance vessels; first and second small mesenteric artery branches obtained from spontaneously hypertensive rats (SHR, 6 and 16 weeks old) and age-matched Wistar Kyoto rats (WKY)]. Maximal response to noradrenaline in the presence of extracellular Ca2+ is not affected …

medicine.medical_specialtyCaptoprilSympathetic Nervous SystemNifedipineAdrenergicAngiotensin-Converting Enzyme InhibitorsBlood PressureRats Inbred WKYMuscle Smooth VascularNorepinephrineNifedipineRats Inbred SHRInternal medicinemedicine.arteryPrazosinAnimalsVasoconstrictor AgentsMedicineMesenteric arteriesAdrenergic alpha-AntagonistsPharmacologyAortabusiness.industryCaptoprilPrazosinCalcium Channel BlockersMesenteric ArteriesRatsEndocrinologyBlood pressuremedicine.anatomical_structurecardiovascular systemMolecular MedicineCalciumbusinessMuscle Contractionmedicine.drugArteryJournal of Pharmacology and Experimental Therapeutics
researchProduct

Expression of Wild-Type and Variant Estrogen Receptor Alpha in Liver Carcinogenesis and Tumor Progression.

2011

Although estrogen receptors (ERs) are expressed in human hepatocellular carcinoma (HCC), several clinical trials have failed to demonstrate the efficacy of antiestrogen treatment in HCC patients. Recently, the identification of several ER splicing variants has enlightened the complex nature of estrogen signaling in peripheral tissues; this may help understanding estrogen role in either nontumoral or malignant nonclassical target organs, including liver. In this work we have investigated mRNA expression of wild-type and splice variants of ERα in nontumoral, cirrhotic, and malignant human liver, as well as in HCC cell lines, using an exon-specific reverse transcription polymerase chain reacti…

medicine.medical_specialtyCarcinoma Hepatocellularmedicine.drug_classEstrogen receptorBiologyBiochemistryAromataseCell Line TumorInternal medicineGene OrderGeneticsmedicineHumansRNA MessengerneoplasmsMolecular BiologyLiver NeoplasmsEstrogen Receptor alphaWild typeExonsHep G2 Cellsmedicine.diseaseAntiestrogenGene Expression Regulation NeoplasticReverse transcription polymerase chain reactionAlternative SplicingCell Transformation NeoplasticEndocrinologyLiverEstrogenTumor progressionHepatocellular carcinomaCancer researchMolecular MedicineEstrogen receptor alphaLiver carcinogenesis Estrogen receptors tumor progressionBiotechnology
researchProduct

Effects of Norepinephrine and Cardiotrophin-1 on Phospholipase D Activity and Incorporation of Myristic Acid Into Phosphatidylcholine in Rat Heart

2004

The present study is part of a project on phospholipase D (PLD) in cardiac hypertrophy and analyzed effects on PLD activity of two growth stimuli, norepinephrine (NE) and cardiotrophin-1 (CT-1), in incubated rat heart. Phosphatidylcholine (PC) was labeled by 3H-myristic acid. PLD produced 3H-phosphatidylethanol (3H-PEth) from 3H-PC in the presence of ethanol and maintained a basal formation of 3H-PEth. Short-term and long-term exposure to NE for 2 or 13 h, respectively, enhanced the formation of 3H-PEth, which was blocked by prazosin. Long-term pretreatment with NE or CT-1 increased the incorporation of 3H-myristic acid into PC, which was blocked by atenolol. When the 3H-PEth formation was …

medicine.medical_specialtyCardiotrophin 1Heart VentriclesMyristic acidStimulationIn Vitro TechniquesMyristic AcidRats Sprague-DawleyNorepinephrinechemistry.chemical_compoundReceptors Adrenergic alpha-1Internal medicinePhosphatidylcholineReceptors Adrenergic betaPhospholipase DmedicinePrazosinAnimalsPhospholipase D activityPharmacologyChemistryPhospholipase DMyocardiumlcsh:RM1-950AtenololRatsEnzyme Activationenzymes and coenzymes (carbohydrates)lcsh:Therapeutics. PharmacologyEndocrinologyPhosphatidylcholinesCytokinesMolecular Medicinelipids (amino acids peptides and proteins)Adrenergic alpha-Agonistsmedicine.drugJournal of Pharmacological Sciences
researchProduct

Dihydrocucurbitacin B, isolated from Cayaponia tayuya, reduces damage in adjuvant-induced arthritis

2005

23,24-Dihydrocucurbitacin B, from the anti-rheumatic plant Cayaponia tayuya, was tested on arthritis induced by adjuvant to corroborate the anti-inflammatory properties of this plant. Arthritis was induced in Lewis rats; the resulting arthritic rats were then treated with dihydrocucurbitacin B (1 mg/kg orally, daily, 1 week). The effect of dihydrocucurbitacin B on the synthesis, release, and activity of pro-inflammatory enzymes (elastase, cyclooxygenase-2, and nitric oxide synthase-2) as well as its effect on different mediators (tumor necrosis factor-alpha and interleukin-1beta) were determined. Dihydrocucurbitacin B modified the evolution of the clinical symptoms, reducing the swelling an…

medicine.medical_specialtyCell Survivalmedicine.medical_treatmentAnti-Inflammatory AgentsAdministration OralNitric Oxide Synthase Type IIPainArthritisPlant RootsDinoprostoneCell LineNitric oxidechemistry.chemical_compoundSuperoxidesInternal medicinemedicineAnimalsLymphocytesNitritesPharmacologyDose-Response Relationship DrugPancreatic ElastasebiologyPlant Extractsbusiness.industryMacrophagesElastasemedicine.diseasebiology.organism_classificationArthritis ExperimentalTriterpenesCayaponia tayuyaRatsEnzyme ActivationNitric oxide synthaseCucurbitaceaeEndocrinologyCytokinechemistryCyclooxygenase 2Rats Inbred LewAntirheumatic AgentsToxicitybiology.proteinCytokinesFemaleTumor necrosis factor alphabusinessPhytotherapyEuropean Journal of Pharmacology
researchProduct

Medical significance of peroxisome proliferator-activated receptors.

1999

Peroxisome proliferator-activated receptors (PPAR) were discovered in 1990, ending 25 years of uncertainty about the molecular mechanisms of peroxisome proliferation. Subsequently, PPARs have improved our understanding of adipocyte differentiation. But there is more to PPARs than solving a puzzle about an organelle (the peroxisome) long considered an oddity, and their medical significance goes beyond obesity too. Enhanced PPAR type alpha expression protects against cardiovascular disorders though the role of enhanced PPARgamma expression seems less favourable. PPAR mechanisms, mainly via induction of more differentiated cell phenotypes, protect against some cancers. The differentiation of m…

medicine.medical_specialtyCellular differentiationPeroxisome ProliferationPeroxisome proliferator-activated receptorReceptors Cytoplasmic and NuclearBiologyMicrobodiesInternal medicineNeoplasmsmedicineAdipocytesAnimalsHumansReceptorRegulation of gene expressionchemistry.chemical_classificationResearchFatty AcidsCell DifferentiationGeneral MedicinePeroxisomeEndocrinologychemistryNuclear receptorGene Expression RegulationCardiovascular DiseasesCancer researchPeroxisome proliferator-activated receptor alphaOxidation-ReductionTranscription FactorsLancet (London, England)
researchProduct

BMP-2 and bFGF release and in vitro effect on human osteoblasts after adsorption to bone grafts and biomaterials.

2012

Objectives Combination of scaffolds and growth factors is a promising option for several clinical problems in bone biomaterials. Simplified growth factor loading by adsorption from aqueous solution is one important option for this technology. We evaluated the adsorption followed by PBS rinsing, release and biological effect of transient loading with basic fibroblast growth factor (bFGF) and bone morphogenic protein 2 (BMP-2) on fresh frozen bone, processed bone matrix, collagen, and a ceramic material with immunofluorescence, enzyme-linked immunosorbent assay (ELISA), and qRT-PCR. Materials and methods The study consisted of three in vitro experiments (immunofluorescence, ELISA, and qRT-PCR…

medicine.medical_specialtyCeramicsTime Factorsmedicine.medical_treatmentBasic fibroblast growth factorOsteocalcinCell Culture TechniquesBone MatrixBone Morphogenetic Protein 2Fluorescent Antibody TechniqueBiocompatible MaterialsCore Binding Factor Alpha 1 SubunitEnzyme-Linked Immunosorbent AssayBone healingMatrix (biology)Bone morphogenetic proteinBone morphogenetic protein 2Bone and Boneschemistry.chemical_compoundmedicineAnimalsHumansCells CulturedOsteoblastsbiologyTissue ScaffoldsReverse Transcriptase Polymerase Chain ReactionGrowth factorOsteoblastAlkaline PhosphataseSurgerymedicine.anatomical_structureDurapatitechemistryDelayed-Action PreparationsOsteocalcinbiology.proteinBiophysicsNanoparticlesFibroblast Growth Factor 2AdsorptionCollagenOral SurgeryBiomarkersClinical oral implants research
researchProduct

Dual specificity phosphatase 1 knockout mice show enhanced susceptibility to anaphylaxis but are sensitive to glucocorticoids.

2007

Dual specificity phosphatase DUSP1 (otherwise known as mitogen-activated phosphatase 1 or MKP-1) dephosphorylates MAPKs, particularly p38, and negatively regulates innate immunity. Recent studies have shown that the DUSP1 gene is transcriptionally up-regulated by glucocorticoids (GCs) and that the antiinflammatory action of GCs is impaired in DUSP1-/- mice. Here we show that GC-mediated dephosphorylation of ERK-1 and ERK-2 activated by IgE receptor cross-linking is unimpaired in bone marrow-derived mast cells (BMMCs) of DUSP1-/- mice. Dephosphorylation of phospho-p38 MAPK is impaired but only at early times of GC treatment. Proinflammatory cytokine and chemokine gene expression (CCL2, IL-6,…

medicine.medical_specialtyChemokinePhosphataseImmunoglobulin Ep38 Mitogen-Activated Protein KinasesProinflammatory cytokineDephosphorylationMiceEndocrinologyInternal medicineSepsisDual-specificity phosphatasemedicineAnimalsGenetic Predisposition to DiseaseMolecular BiologyAnaphylaxisGlucocorticoidsMice KnockoutMitogen-Activated Protein Kinase 1Mice Inbred C3HMitogen-Activated Protein Kinase 3biologyInterleukin-6Tumor Necrosis Factor-alphaDegranulationDual Specificity Phosphatase 1General MedicineMice Inbred C57BLEndocrinologyGene Expression RegulationMice Inbred DBAbiology.proteinCytokinesTumor necrosis factor alphaMolecular endocrinology (Baltimore, Md.)
researchProduct

Toxisches Schock Syndrom

1990

We report about a one year old girl with toxic shock syndrome (TSS), which was confirmed by a significant rise of TSST-1 titers. In addition to known manifestations of TSS, to our knowledge this is the first report about development of polyserositis in this disease. Tumor necrosis factor (TNF) was elevated at initial evaluation and fell under treatment with cortisone. This finding is in contrast to in-vitro observations. We believe that the use of cortisone in TSS warrants further investigation.

medicine.medical_specialtyChemotherapygenetic structuresbusiness.industrymedicine.medical_treatmentToxic shock syndromebacterial infections and mycosesmedicine.diseaseGastroenterologyInternal medicinePediatrics Perinatology and Child HealthImmunologymedicineTumor necrosis factor alphaCortisonebusinessmedicine.drugKlinische Pädiatrie
researchProduct

Anti-androgens for the treatment of hirsutism.

2002

Many alternatives exist for treating hirsutism. Based on an analysis of scientific literature and on the experiences of the author, the most common anti-androgen agents are discussed in this review. Androgen receptor blockers (cyproterone acetate, flutamide and spironolactone), 5 alpha-reductase inhibitors (finasteride) and androgen-suppressing agents (gonadotrophin-releasing hormone [GnRH] agonists, oestroprogestins, corticosteroids and insulin-sensitising agents) are evaluated and compared. The importance of diagnosis in choosing the most appropriate anti-androgen treatment is also discussed.

medicine.medical_specialtyCholestenone 5 alpha-ReductaseHirsutismAnti-Androgenurologic and male genital diseasesFlutamideGonadotropin-Releasing Hormonechemistry.chemical_compoundInternal medicineAndrogen Receptor AntagonistsMedicineHumansPharmacology (medical)Androgen Receptor AntagonistshirsutismPharmacologybusiness.industryCyproterone acetateAndrogen AntagonistsGeneral Medicinemedicine.diseaseAndrogen receptorEndocrinologyTreatment OutcomechemistrySpironolactoneFinasterideAndrogensFemalebusinessOxidoreductasesExpert opinion on investigational drugs
researchProduct

Cost Effectiveness of Peginterferon ??-2a Plus Ribavirin versus Interferon ??-2b Plus Ribavirin as Initial Therapy for Treatment-Naive Chronic Hepati…

2004

Introduction: In adults with previously untreated chronic hepatitis C (CHC), the combination of peginterferon α-2a plus ribavirin produces a higher rate of sustained virological response (SVR) than interferon α-2b plus ribavirin, but it is still unproven whether this increase is cost effective. The objective of this study was to determine if the gain in SVR with peginterferon α-2a plus ribavirin is worth the incremental cost. Methods: We constructed a Markov model of disease progression in which cohorts of patients received peginterferon α-2a plus ribavirin or interferon α-2b plus ribavirin for 48 weeks (hepatitis C virus [HCV] genotype 1 and non-1 patients with fibrosis) or 24 weeks (genot…

medicine.medical_specialtyCirrhosisGenotypeCost effectivenessCost-Benefit AnalysisHepatitis C virusInterferon alpha-2medicine.disease_causeAntiviral AgentsSensitivity and SpecificityGastroenterologypeginterferon alpha2aPolyethylene Glycolschemistry.chemical_compoundchronic hepatitiInterferonInternal medicineRibavirinmedicineHumansRandomized Controlled Trials as Topicalpha2b interferonAntiviral AgentPharmacologybusiness.industryHealth PolicyRibavirinPublic Health Environmental and Occupational HealthInterferon-alphavirus diseasesHealth Care CostsHepatitis CHepatitis C Chronicmedicine.diseaseMarkov ChainsRecombinant Proteinsdigestive system diseasesModels EconomicTreatment OutcomechemistryImmunologyQuality of LifePeginterferon alfa-2bDrug Therapy CombinationbusinessPeginterferon alfa-2amedicine.drugPharmacoEconomics
researchProduct